MedPath

iCAD Inc

🇺🇸United States
Ownership
-
Employees
69
Market Cap
$41.3M
Website

RadNet to Acquire iCAD for $100 Million, Advancing AI-Powered Breast Cancer Detection

RadNet Inc. has announced plans to acquire iCAD Inc. for approximately $100 million, uniting two leading companies in AI-powered cancer detection technology with a focus on breast cancer screening.

iCAD and Koios Medical Unite to Launch Comprehensive AI-Powered Breast Cancer Detection Platform

iCAD and Koios Medical announce strategic partnership to integrate ProFound AI Breast Health Suite with Koios SmartUltrasound, creating a comprehensive AI-powered breast cancer detection solution.

iCad's AI-Powered Breast Cancer Detection Tech ProFound Detection version 4.0 Receives FDA Clearance

iCad's ProFound Detection version 4.0, an AI-powered solution for digital breast tomosynthesis (DBT), has received FDA clearance, marking a significant advancement in cancer detection technology.

iCAD's ProFound Detection 4.0 Receives FDA Clearance for Enhanced Breast Cancer Detection

iCAD's ProFound Detection Version 4.0, an AI-powered solution for digital breast tomosynthesis, has received FDA clearance, enhancing cancer detection and specificity.

© Copyright 2025. All Rights Reserved by MedPath